NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma

Plain-language summary

This study examines the use of next-generation sequencing (NGS)-based germline and somatic BRCA genetic testing in patients with ovarian carcinoma. It enrolls patients aged 18 and older with a histologically confirmed diagnosis of ovarian, fallopian tube, or primary peritoneal cancer. It is in Phase 4; it is not currently recruiting but is ongoing (active, not recruiting).

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 4

Status

Active, not recruiting

Sponsor

European Institute of Oncology

Intervention

BRCA testing

Start date

6/12/2018

Estimated completion

12/30/2025

Countries

Italy

Related genes

Locations

• Milan, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. age 18 or higher
2. has signed informed consent
3. histologically confirmed ovarian cancer, Fallopian tube cancer, or primary peritoneal cancer.
4. Any stage is admitted
5. Any histology is admitted
6. availability of surgical/bioptic material. Formalin-fixed, paraffinembedded or frozen specimens are both allowed, with no time limitation

Exclusion Criteria:

1\. unable or unwilling to receive genetic counseling